On August 4, 2020, Messino Cancer Centers (MCC), a partner practice of American Oncology Network, LLC (AON), announced that medical oncologist and the 2011-2014 member of the North Carolina Oncology Association (NCOA) Board of Directors Michael Messino, MD, received North Carolina’s highest award for state service granted by the Office of the Governor. The Order of the Long Leaf Pine is an honor granted by the State of North Carolina to individuals who have shown extraordinary service to the state. Senator Terry Van Duyn presented the award to Dr. Messino on July 31, 2020.
Read the press release.
Proposed changes to the CY 2021 Physician Fee Schedule are aimed at reducing burden, recognizing clinicians for the time they spend taking care of patients, removing unnecessary measures, and making it easier for clinicians to be on the path towards value-based care. During this listening session, CMS experts briefly cover provisions from the proposed rule and address your clarifying questions to help you formulate your written comments for formal submission:
When: Thursday, August 13, 2020, 1:30-3:00 pm ET.
Who: Medicare Part B fee-for-service clinicians; office managers and administrators; state and national associations that represent health care providers; and other stakeholders.
Click here to register
CMS encourages you to review the following materials prior to the call:
On August 4, 2020, the Centers for Medicare & Medicaid Reimbursement (CMS) issued the calendar year (CY) 2021 Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment Proposed Rule (CMS-1736-P). ACCC and council are reviewing these proposed rules and will be providing comments.
Until this analysis is complete, read the proposed OPPS rule and the proposed PFS rule. Then register for ACCC’s August 14 webcast on The 2021 Proposed PFS and OPPS Rules: Practical Implications and Considerations to gain insight into how these proposed rules will affect your cancer program.
On August 4, 2020, the Centers for Medicare & Medicaid Reimbursement (CMS) issued the calendar year (CY) 2021 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment Proposed Rule (CMS-1736-P). ACCC and counsel are reviewing these proposed rules and will be providing comments.
Until this analysis is complete, read the proposed rule. Then register for ACCC’s August 14 webcast on The 2021 Proposed PFS and OPPS Rules: Practical Implications and Considerations to gain insight into how these proposed rules will affect your cancer program.
On July 31, 2020 MorphoSys and Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Read corporate press release.
Read FDA announcement.
The Centers for Medicare & Medicaid Services (CMS) continues to host regularly scheduled COVID-19 stakeholder engagement calls. These include office hours calls, weekly site-specific calls for COVID-19 care, and lessons from the front lines. Calls are open to members of the healthcare community and are intended to provide updates, share best practices among peers, and offer attendees an opportunity to ask questions of CMS and other subject matter experts.
CMS COVID-19 Office Hours Call (Tuesdays at 5:00-6:00 pm ET)
Tuesday, August 4, 2020
Toll Free Attendee Dial In: 833-614-0820; Access Code: 3296947
Audio Webcast Link
Tuesday, August 11, 2020
Toll Free Attendee Dial In: 833-614-0820; Access Code: 3498643
Audio Webcast Link
Lessons from the Front Lines: COVID-19 (twice a month on Fridays at 12:30 - 2:00 pm ET)
Friday, August 7, 2020
Toll Free Attendee Dial In: 833-614-0820; Access Code: 4695240
Audio Webcast Link
See the CMS Coronavirus (COVID-19) Partner Toolkit for a full list of sessions and times. Audio webcast links and dial-in information is also available on this page. All previous session recordings and transcripts are posted to the CMS podcast page.
Access CMS' Medicare COVID-19 Data Snapshot and additional information here.
ASCO-ACCC Request for Ideas (RFI)
The ASCO-ACCC Request for Ideas (RFI) seeks novel strategies and practical solutions to increase participation of under-represented racial and ethnic populations in cancer treatment trials. The ASCO-ACCC Steering Group will review and select ideas that may be modified, combined, implemented, and evaluated by ASCO and ACCC. The ideas submitted may be implemented and evaluated through the ASCO Targeted Agent and Profiling Utilization Registry (TAPURTM) Study, for example.
Criteria used to review and prioritize proposed ideas will include the potential to address racial and ethnic disparities in cancer treatment trials, replicability of the strategy, and indications that the submitter has demonstrated a commitment to equitable cancer care, among others. Individuals who submit ideas will be given an opportunity to work on the idea implementation, if interested.
The RFI is open for participation now through August 24, 2020. Learn more.
What: HHS Telemedicine Hack is a 10-week virtual, peer-to-peer learning community to accelerate telemedicine implementation for ambulatory providers. Components include: five teleECHO sessions; five virtual “office hour” discussion panels; and inter-session peer-to-peer learning facilitated via virtual discussion boards. CME/CEU credits are available at no cost to participants.
When: Telemedicine Hack sessions will take place on Wednesdays, from July 22–September 23, 2020, Noon–1 PM ET
How to sign up: Click here to register.
See the HHS Telemedicine Hack Flyer for more information.
On July 7, 2020, the U.S. Food and Drug Administration (FDA) and Health Canada have approved decitabine and cedazuridine (Inqovi, Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd.) tablets for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).
Approval was based on data from the ASCERTAIN phase 3 study and supporting phase 1 and 2 clinical studies. The ASCERTAIN phase 3 study evaluated the five-day, decitabine exposure equivalence between oral Inqovi® and intravenous decitabine. The safety and efficacy of Inqovi® was also assessed in the clinical studies.
Read corporate announcement.
On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck & Co.) for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).
MSI-H/dMMR testing is required prior to initiating treatment with Keytruda in these patients. For the MSI-H/dMMR indication, select patients for treatment with Keytruda as a single agent based on MSI-H/dMMR status in tumor specimens. An FDA-approved test for the detection of MSI-H or dMMR is not currently available.
Read prescribing information and medication guide.
On June 24, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck & Co.) injection 100 mg for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
Read FDA announcement and prescribing information.
On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo, Genentech) injection, for subcutaneous use.
Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for:
Phesgo™ is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Read corporate announcement.
Billing and coding sheet.